Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsTOPICALGeneric

EMLA

LIDOCAINE; PRILOCAINE

Standard Dose
2.5%;2.5%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview EMLA is listed in Drugs@FDA under application 020962 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient LIDOCAINE; PRILOCAINE Form and strength DISC;TOPICAL - 2.5%;2.5% Sponsor ASTRAZENECA Submission history Latest submission status date: 2002-10-09 00:00:00.

Structured Monograph

Clinical summary

Approval overview EMLA is listed in Drugs@FDA under application 020962 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient LIDOCAINE; PRILOCAINE Form and strength DISC;TOPICAL - 2.5%;2.5% Sponsor ASTRAZENECA Submission history Latest submission status date: 2002-10-09 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.